EP4719443A1 - Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose - Google Patents

Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose

Info

Publication number
EP4719443A1
EP4719443A1 EP24816687.8A EP24816687A EP4719443A1 EP 4719443 A1 EP4719443 A1 EP 4719443A1 EP 24816687 A EP24816687 A EP 24816687A EP 4719443 A1 EP4719443 A1 EP 4719443A1
Authority
EP
European Patent Office
Prior art keywords
cell
cells
immune
genetically modified
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816687.8A
Other languages
English (en)
French (fr)
Inventor
Tania KONRY
Matthew Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeastern University Boston
Original Assignee
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeastern University Boston filed Critical Northeastern University Boston
Publication of EP4719443A1 publication Critical patent/EP4719443A1/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/30Coculture with; Conditioned medium produced by tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/003D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24816687.8A 2023-06-02 2024-06-03 Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose Pending EP4719443A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470820P 2023-06-02 2023-06-02
PCT/US2024/032321 WO2024250037A1 (en) 2023-06-02 2024-06-03 Targeted immune cell therapy utilizing trail and tnf mediated apoptosis

Publications (1)

Publication Number Publication Date
EP4719443A1 true EP4719443A1 (de) 2026-04-08

Family

ID=93658569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816687.8A Pending EP4719443A1 (de) 2023-06-02 2024-06-03 Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose

Country Status (2)

Country Link
EP (1) EP4719443A1 (de)
WO (1) WO2024250037A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560953T3 (pl) * 2014-12-24 2024-05-13 Autolus Limited Komórka
EP3889176A1 (de) * 2016-01-15 2021-10-06 Berkeley Lights, Inc. Verfahren zur herstellung patientenspezifischer antikrebstherapeutika und verfahren zur behandlung davon
WO2020247313A1 (en) * 2019-06-01 2020-12-10 Northeastern University Microfluidic device for high-throughput screening of tumor cell adhesion and motility
US12577290B2 (en) * 2021-03-04 2026-03-17 Allogene Therapeutics, Inc. FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death

Also Published As

Publication number Publication date
WO2024250037A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US20250197471A1 (en) Methods for the treatment of b cell malignancies using adoptive cell therapy
Li et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
Freeman et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
CN110730908B (zh) 表达前列腺特异性膜抗原(psma)或其修饰形式的工程化细胞及相关方法
Roussel et al. Functional characterization of PD1+ TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade
Coles et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
Parry et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma
US20210190763A1 (en) Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (car) t cells
CA2954414A1 (en) Engineered cells for adoptive cell therapy
BR112020011223A2 (pt) marcadores fenotípicos para terapia celular e mé-todos relacionados
Shapiro et al. First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer
Zhu et al. CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
CN116157125A (zh) 针对bcma的t细胞疗法与免疫调节化合物的组合
Sullivan et al. An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells
CN108778312B (zh) 使用基于细胞的疗法治疗癌症和传染病的方法
Zhu et al. CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation
EP4719443A1 (de) Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose
WO2020233503A1 (en) Detection method
Sullivan Development of integrated platform of lymphocyte phenotyping, and immunotherapy validation in single cell and 3D droplet microfluidic systems
RU2346279C2 (ru) СПОСОБ ОПРЕДЕЛЕНИЯ УРОВНЯ мРНК КАТАЛИТИЧЕСКОЙ СУБЪЕДИНИЦЫ ТЕЛОМЕРАЗЫ (hTERT)
Rodin Unconventional T cells in colon adenocarcinomas
RU2776823C2 (ru) Композиции, изделия и способы, связанные с дозированием в клеточной терапии
WO2026060102A1 (en) Methodology for sorting, expansion, and transcriptomics analysis of killer t-cells
WO2025196287A1 (en) T cell lineages with early-differentiated characteristics derived from solid tumors as next generation cancer therapy and diagnostics

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR